In vitro susceptibility testing of fluoroquinolone activity against salmonella: Recent changes to CLSI standards

Clinical Infectious Diseases

Volumn 55, Issue 8, 2012, Pages 1107-1113

  Humphries, Romney M ^a   Fang, Ferric C ^b   Aarestrup, Frank M ^c   Hindler, Janet A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; STANDARD;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; SALMONELLA; SALMONELLA INFECTIONS; UNITED STATES;

EID: 84866640704     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis600     Document Type: Review

References (79)

1. Voetsch AC, Van Gilder TJ, Angulo FJ, et al. FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis 2004; 38(Suppl 3):S127-34.
2. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32:263-9.
3. Schlundt J, Toyofuku H, Jansen J, Herbst SA. Emerging food-borne zoonoses. Rev Sci Tech 2004; 23:513-33.
4. Majowicz SE, Musto J, Scallan E, et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 2010; 50:882-9.
5. Neill MA, Opal SM, Heelan J, et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114:195-9.
6. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-51.
7. Morpeth SC, Ramadhani HO, Crump JA. Invasive non-Typhi Salmonella disease in Africa. Clin Infect Dis 2009; 49:606-11.
8. Vandenberg O, Nyarukweba DZ, Ndeba PM, et al. Microbiologic and clinical features of Salmonella species isolated from bacteremic children in eastern Democratic Republic of Congo. Pediatr Infect Dis J 2010; 29:504-10.
9. Kingsley RA, Msefula CL, Thomson NR, et al. Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res 2009; 19:2279-87.
10. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008; 86:260-8.
11. Butt T, Ahmad RN, Salman M, Kazmi SY. Changing trends in drug resistance among typhoid salmonellae in Rawalpindi, Pakistan. East Mediterr Health J 2005; 11:1038-44.
12. WHO. The Diagnosis, treatment and prevention of typhoid fever. Available at: http://www.who.int/vaccine-research/documents/en/typhoid-diagnosis.pdf. Accessed 20 February 2012.
13. Le Hello S, Hendriksen RS, Doublet B, et al. International spread of an epidemic population of Salmonella enterica serotype Kentucky ST198 resistant to ciprofloxacin. J Infect Dis 2011; 204:675-84.
14. Xia S, Hendriksen RS, Xie Z, et al. Molecular characterization and antimicrobial susceptibility of Salmonella isolates from infections in humans in Henan Province, China. J Clin Microbiol 2009; 47:401-9.
15. Dutta S, Sur D, Manna B, et al. Emergence of highly fluoroquinoloneresistant Salmonella enterica serovar Typhi in a community-based fever surveillance from Kolkata, India. Int J Antimicrob Agents 2008; 31:387-9.
16. Keddy KH, Smith AM, Sooka A, Ismail H, Oliver S. Fluoroquinoloneresistant typhoid, South Africa. Emerg Infect Dis 2010; 16:879-80.
17. Crump JA, Medalla FM, Joyce KW, et al. Antimicrobial resistance among invasive nontyphoidal Salmonella enterica isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007. Antimicrob Agents Chemother 2011; 55:1148-54.
18. Keddy KH, Sooka A, Letsoalo ME, et al. Sensitivity and specificity of typhoid fever rapid antibody tests for laboratory diagnosis at two sub-Saharan African sites. Bull World Health Organ 2011; 89:640-7.
19. Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac (6′)Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J Clin Microbiol 2009; 47:2751-8.
20. Testing EUCoAS. Ciprofloxacin/Salmonella spp EUCAST MIC Distribution-Reference Database 2012-02-20. Available at: http://217.70. 33.99/Eucast2/regShow.jsp?Id=4252. Accessed 20 February 2012.
21. Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000; 283:2668-73.
22. Cooke FJ, Wain J. The emergence of antibiotic resistance in typhoid fever. Travel Med Infect Dis 2004; 2:67-74.
23. Crump JA, Kretsinger K, Gay K, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob Agents Chemother 2008; 52:1278-84.
24. Lynch MF, Blanton EM, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302:859-65.
25. Chau TT, Campbell CM, Galindo N, et al. Antimicrobial drug resistance of Salmonella serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2010; 51:4315-23.
26. Chuang CH, Su LH, Perera J, et al. Surveillance of antimicrobial resistance of Salmonella enterica serotype Typhi in seven Asian countries. Epidemiol Infect 2009; 137:266-9.
27. Smith AM, Govender N, Keddy KH. Quinolone-resistant Salmonella Typhi in South Africa, 2003-2007. Epidemiol Infect 2010; 138:86-90.
28. Sirichote P, Bangtrakulnonth A, Tianmanee K, et al. Serotypes and antimicrobial resistance of Salmonella enterica ssp in central Thailand, 2001-2006. Southeast Asian J Trop Med Public Health 2010; 41:1405-15.
29. Chau TT, Campbell JI, Galindo CM, et al. Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007; 51:4315-23.
30. Roumagnac P, Weill FX, Dolecek C, et al. Evolutionary history of Salmonella Typhi. Science 2006; 314:1301-4.
31. Wain J, Hoa NT, Chinh NT, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404-10.
32. Parry C, Wain J, Chinh NT, Vinh H, Farrar JJ. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 1998; 351:1289.
33. Renuka K, Kapil A, Kabra SK, et al. Reduced susceptibility to ciprofloxacin and gyra gene mutation in North Indian strains of Salmonella enterica serotype Typhi and serotype Paratyphi A. Microb Drug Resist 2004; 10:146-53.
34. Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 2004; 4:36.
35. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 2005; 5:37.
36. Boswell TC, Coleman DJ, Purser NJ, Cobb RA. Development of quinolone resistance in salmonella: failure to prevent splenic abscess. J Infect 1997; 34:86-7.
37. Vasallo FJ, Martin-Rabadan P, Alcala L, Garcia-Lechuz JM, Rodriguez-Creixems M, Bouza E. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis 1998; 26:535-6.
38. Piddock LJ, Whale K, Wise R. Quinolone resistance in salmonella: clinical experience. Lancet 1990; 335:1459.
39. Piddock LJ, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother 1993; 37:662-6.
40. Chang CM, Lee HC, Lee NY, Huang GC, Lee IW, Ko WC. Cefotaxime- ciprofloxacin combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy. Pharmacotherapy 2006; 26:1671-4.
41. Helms M, Simonsen J, Molbak K. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. J Infect Dis 2004; 190:1652-4.
42. Molbak K, Baggesen DL, Aarestrup FM, et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999; 341:1420-5.
43. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003; 47:827-9.
44. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 2003; 37:75-81.
45. Rupali P, Abraham OC, Jesudason MV, et al. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn Microbiol Infect Dis 2004; 49:1-3.
46. Walker RA, Skinner JA, Ward LR, Threlfall EJ. LightCycler gyrA mutation assay (GAMA) identifies heterogeneity in GyrA in Salmonella enterica serotypes Typhi and Paratyphi A with decreased susceptibility to ciprofloxacin. Int J Antimicrob Agents 2003; 22:622-5.
47. Hakanen AJ, Lindgren M, Huovinen P, Jalava J, Siitonen A, Kotilainen P. New quinolone resistance phenomenon in Salmonella enterica: nalidixic acid-susceptible isolates with reduced fluoroquinolone susceptibility. J Clin Microbiol 2005; 43:5775-8.
48. Cooke FJ, Wain J, Threlfall EJ. Fluoroquinolone resistance in Salmonella Typhi. BMJ 2006; 333:353-4.
49. Gay K, Robicsek A, Strahilevitz J, et al. Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis 2006; 43:297-304.
50. Lindgren MM, Kotilainen P, Huovinen P, et al. Reduced fluoroquinolone susceptibility in Salmonella enterica isolates from travelers, Finland. Emerg Infect Dis 2009; 15:809-12.
51. Sjolund-Karlsson M, Folster JP, Pecic G, et al. Emergence of plasmidmediated quinolone resistance among non-Typhi Salmonella enterica isolates from humans in the United States. Antimicrob Agents Chemother 2009; 53:2142-4.
52. Nath G, Maurya P. Drug resistance patterns in Salmonella enterica subspecies enterica serotype Typhi strains isolated over a period of two decades, with special reference to ciprofloxacin and ceftriaxone. Int J Antimicrob Agents 2010; 35:482-5.
53. Medalla F, Sjolund-Karlsson M, Shin S, et al. Ciprofloxacin-resistant Salmonella enterica Serotype Typhi, United States, 1999-2008. Emerg Infect Dis 2011; 17:1095-8.
54. Song Y, Roumagnac P, Weill FX, et al. A multiplex single nucleotide polymorphism typing assay for detecting mutations that result in decreased fluoroquinolone susceptibility in Salmonella enterica serovars Typhi and Paratyphi A. J Antimicrob Chemother 2010; 65:1631-41.
55. Accou-Demartin M, Gaborieau V, Song Y, et al. Salmonella enterica Serotype Typhi with nonclassical quinolone resistance phenotype. Emerg Infect Dis 2011; 17:1091-4.
56. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? Clin Microbiol Infect 2008; 14:295-7.
57. Cavaco LM, Hendriksen RS, Aarestrup FM. Plasmid-mediated quinolone resistance determinant qnrS1 detected in Salmonella enterica serovar Corvallis strains isolated in Denmark and Thailand. J Antimicrob Chemother 2007; 60:704-6.
58. Hopkins KL, Day M, Threlfall EJ. Plasmid-mediated quinolone resistance in Salmonella enterica, United Kingdom. Emerg Infect Dis 2008; 14:340-2.
59. Cavaco LM, Hasman H, Xia S, Aarestrup FM. qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. Antimicrob Agents Chemother 2009; 53:603-8.
60. Gunell M, Webber MA, Kotilainen P, et al. Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob Agents Chemother 2009; 53:3832-6.
61. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 2005; 56:463-9.
62. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:629-40.
63. Sjolund-Karlsson M, Howie R, Rickert R, et al. Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USA. Emerg Infect Dis 2010; 16:1789-91.
64. Yu F, Chen Q, Yu X, et al. High prevalence of plasmid-mediated quinolone resistance determinant aac(6′)-Ib-cr amongst Salmonella enterica serotype Typhimurium isolates from hospitalised paediatric patients with diarrhoea in China. Int J Antimicrob Agents 2011; 37:152-5.
65. Fashae K, Ogunsola F, Aarestrup FM, Hendriksen RS. Antimicrobial susceptibility and serovars of Salmonella from chickens and humans in Ibadan, Nigeria. J Infect Dev Ctries 2010; 4:484-94.
66. Booker BM, Smith PF, Forrest A, et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 2005; 49:1775-81.
67. Allou N, Cambau E, Massias L, Chau F, Fantin B. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 2009; 53:4292-7.
68. de Toro M, Rojo-Bezares B, Vinue L, Undabeitia E, Torres C, Saenz Y. In vivo selection of aac(6′)-Ib-cr and mutations in the gyrA gene in a clinical qnrS1-positive Salmonella enterica serovar Typhimurium DT104B strain recovered after fluoroquinolone treatment. J Antimicrob Chemother 2010; 65:1945-9.
69. Parry CM, Thuy CT, Dongol S, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54:5201-8.
70. Arlet G, Barrett TJ, Butaye P, Cloeckaert A, Mulvey MR, White DG. Salmonella resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microbes Infect 2006; 8:1945-54.
71. CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2010. Atlanta, Georgia: US Department of Health and Human Services, 2010.
72. Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrugresistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000; 44:1855-9.
73. Parry CM, Ho VA, Phuong le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007; 51:819-25.
74. Capoor MR, Rawat D, Nair D, et al. In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J Med Microbiol 2007; 56(Pt 11):1490-4.
75. Murray A, Coia JE, Mather H, Brown DJ. Ciprofloxacin resistance in non-typhoidal Salmonella serotypes in Scotland, 1993-2003. J Antimicrob Chemother 2005; 56:110-4.
76. Hirose K, Tamura K, Sagara H, Watanabe H. Antibiotic susceptibilities of Salmonella enterica serovar Typhi and S. enterica serovar Paratyphi A isolated from patients in Japan. Antimicrob Agents Chemother 2001; 45:956-8.
77. Parry CM, Vinh H, Chinh NT, et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. PLoS Negl Trop Dis 2011; 5:e1163.
78. Craig WA, Andes DR, Paterson D. In vivo activity of levofloxacin against Salmonella species susceptible and resistant to naladixic acid in the neutropenic murine-thigh infection model. Interscience Conference on Antimicrobial Agents and Chemotheray Vol. A-6, 2006.
79. Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 2008; 3:e2188.